NLS Pharmaceutics to Participate in the 23rd Annual H.C. Wainwright Global Investment Conference

Rhea-AI Summary

NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NASDAQ:NLSPW) announces that CEO Alex Zwyer will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. Investors can access the presentation online starting September 13 at 1:00 PM CET / 7:00 AM ET. This conference includes six industry tracks, highlighting Healthcare & Biotechnology, and offers networking opportunities. NLS is focused on innovative therapies for central nervous system disorders, with its lead candidate, Quilience, targeting narcolepsy and receiving Orphan Drug Designations in the U.S. and Europe.

STANS, SWITZERLAND / ACCESSWIRE / September 8, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Alex Zwyer, Chief Executive Officer and Co-Founder, is scheduled to

present a corporate overview and participate in meetings with investors at the H.C. Wainwright 23^rd Annual Global Investment Conference to be held September 13-15, 2021.

Presentation Details:

H.C. Wainwright Virtual Presentation: Investors may listen to the NLS Pharmaceutics presentation online beginning on September 13th at 1:00pm CET / 7:00am ET via the following link: https://journey.ct.events/view/40da20b0-3c77-4a22-9eac-9a6bb69b96cf. The presentation recording will be available for 90 days from the start of the conference. The H.C. Wainwright Global Investment Conference features six industry tracks including Healthcare & Biotechnology, as well as leading industry keynote speakers & presenting companies, investor meetings, and networking opportunities.

About NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage biopharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex central nervous system disorders. The Company's lead product candidate, Quilience® is a proprietary extended-release formulation of mazindol (mazindol ER), and is being developed for the treatment of narcolepsy. Mazindol is a triple monoamine reuptake inhibitor and partial orexin-2 receptor agonist, which was used for many years to treat patients diagnosed with narcolepsy in compassionate use programs. NLS completed a phase 2 study in the U.S. evaluating Nolazol^Ò (mazindol controlled-release) in adult subjects with ADHD. The study met all primary and secondary endpoints and was well-tolerated. Quilience has received Orphan Drug Designations both in the U.S. and in Europe for the treatment of narcolepsy.

Corporate contact
Alex Zwyer, CEO: +41 41 618 80 00

Investor Relations contact
Cindy Rizzo: +1 908-229-7050
www.nlspharma.com

SOURCE: NLS Pharmaceutics AG

View source version on accesswire.com:
https://www.accesswire.com/663070/NLS-Pharmaceutics-to-Participate-in-the-23rd-Annual-HC-Wainwright-Global-Investment-Conference

FAQ

What will NLS Pharmaceutics present at the H.C. Wainwright conference?

NLS Pharmaceutics will present a corporate overview and engage in investor meetings.

When is the H.C. Wainwright 23rd Annual Global Investment Conference?

The conference will be held from September 13 to 15, 2021.

How can investors access the NLS Pharmaceutics presentation?

Investors can access the presentation online starting September 13 at 1:00 PM CET / 7:00 AM ET via a provided link.

What is Quilience and its relevance for NLS Pharmaceutics?

Quilience is NLS's lead product candidate for narcolepsy, a proprietary extended-release formulation of mazindol.

What designations has Quilience received?

Quilience has received Orphan Drug Designations in both the U.S. and Europe for the treatment of narcolepsy.